



BLA 125409/S-105

SUPPLEMENT APPROVAL

Genentech, Inc.
Attention: Miu Chau, Ph.D.
Regulatory Program Management
1 DNA Way
South San Francisco, CA 94080

Dear Dr. Chau:

Please refer to your Supplemental Biologics License Application (sBLA), dated and received December 12, 2014, submitted under section 351(a) of the Public Health Service Act for Perjeta[®] (pertuzumab).

We acknowledge receipt of your amendments dated March 26, April 2, and 10, 2015.

This Prior Approval supplemental biologics application provides for revisions to update the Warnings and Precautions, Use in Specific Populations, and Patient Counseling Information sections regarding the use of effective contraception during the 7 month washout period when Perjeta is used in combination with trastuzumab.

When the labeling with new pregnancy/lactation content must be submitted to FDA for approval according to the implementation plan of the Pregnancy and Lactation Labeling Rule (PLLR), we recommend that you submit contemporaneous labeling supplements for Herceptin, Kadcyła, and Perjeta to provide for these updates in order to maintain consistency among these labels.

APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical to the enclosed labeling text for the package insert and include the labeling changes proposed in any pending "Changes Being Effectuated" (CBE) supplements. Information on

submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this BLA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in MS Word format that includes the changes approved in this supplemental application.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, contact Amy Tilley, Regulatory Project Manager, at 301-796-3994 or amy.tilley@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Amna Ibrahim, M.D.
Deputy Director
Division of Oncology Products 1
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

AMNA IBRAHIM
05/29/2015